Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
Site Search
White will be the first person living with CF to lead the Board into a new era of CF
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF
The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance